Background Phaeochromocytomas and paragangliomas are neuro-endocrine tumours that occur sporadically and in several hereditary tumour syndromes, including the phaeochromocytoma-paraganglioma syndrome. This syndrome is caused by germline mutations in succinate dehydrogenase B (SDHB), C (SDHC), or D (SDHD) genes. Clinically, the phaeochromocytoma-paraganglioma syndrome is often unrecognised, although 10-30% of apparently sporadic phaeochromocytomas and paragangliomas harbour germline SDH-gene mutations. Despite these fi gures, the screening of phaeochromocytomas and paragangliomas for mutations in the SDH genes to detect phaeochromocytomaparaganglioma syndrome is rarely done because of time and fi nancial constraints. We investigated whether SDHB immunohistochemistry could eff ectively discriminate between SDH-related and non-SDH-related phaeochromocytomas and paragangliomas in large retrospective and prospective tumour series.
Introduction
Phaeochromocytomas and paragangliomas are rare, usually benign, highly vascularised tumours that both originate from neural-crest-derived chromaffi n cells. The term phaeochromocytoma is reserved for intra-adrenal tumours, whereas similar but extra-adrenal tumours are termed paragangliomas. Paragangliomas are subdivided into sympathetic and parasympathetic paragangliomas, depending on their location and catecholamine production. Parasympathetic paragangliomas are located in the head and neck region, and usually do not produce catecholamines, whereas sympathetic paragangliomas are situated along the sympathetic trunk in the abdomen, and usually produce catecholamines. 1 Phaeochromocytomas and paragangliomas occur sporadically and in the context of several inherited tumour syndromes, including multiple endocrine neoplasia type 2 (MEN2, with RET gene germline mutations), von Hippel-Lindau (VHL) disease (caused by germline mutations in the VHL gene), neurofi bromatosis type 1 (NF1, with NF1 gene germline mutations), and the phaeochromocytoma-paraganglioma syndrome. 2, 3 The latter syndrome is the most frequent hereditary condition with manifestation of paragangliomas, and is caused by germline mutations in the SDHB, SDHC, or SDHD genes. The syndrome is characterised by the familial occurrence of phaeochromocytomas or paragangliomas, usually at a young age, and often by multifocal disease with an increased risk of recurrence and an increased frequency of malignancy in the case of SDHB mutations. 4 SDHB, SDHC, and SDHD encode three of four subunits of mitochondrial complex II, the succinate-ubiquinone oxido reductase (succinate dehydrogenase) enzyme located at the crossroads between the mitochondrial aerobic electron transport chain and the tricarboxylic acid cycle. 5 Recent studies showed that SDH inactivation induces angiogenesis and tumorigenesis through the inhibition of hypoxia-inducible factors (HIF)-prolyl hydroxylase. 6 The SDHB, SDHC, and SDHD genes are bona fi de tumour-suppressor genes, as biallelic inactivation is found in phaeochromocytoma-paragangliomasyndrome tumours (inherited inactivating germline mutation and acquired inactivating mutation of the corresponding wild-type allele in the tumour). 7 With the exception of the NF1 syndrome, where the cutaneous café-au-lait spots are characteristic, 8 patients with inherited phaeochromocytomas and paragangliomas often go without clinical detection. In large published series of patients with phaeochromocytomas and paragangliomas, it has been shown that 25-30% of patients have an inherited form and 12% of patients with an apparently sporadic phaeochromocytoma and paraganglioma have unexpected germline mutations in VHL, SDHB, or SDHD genes. 3, [7] [8] [9] The underdiagnosis of patients with inherited phaeochromocytoma and paraganglioma is the result of a combination of factors, including lack of family information, overlap in age distribution between hereditary and sporadic cases, de-novo mutations, incomplete penetrance (SDHB), parent-of-origin eff ects on penetrance (SDHD), phenotypic heterogeneity of the disease, and insuffi cient awareness of clinicians. There is controversy among experts as to whether RET, VHL, SDHB, SDHC, and SDHD genetic testing should be done in all patients with phaeochromocytoma and paraganglioma. Many experts have advocated that molecular genetic testing should be targeted in patients fulfi lling specifi c clinical criteria. 4, [10] [11] [12] However, reliable clinical indicators for the presence of SDHB, SDHC, and SDHD germline mutations in patients with phaeochromocytoma and paraganglioma are often absent.
Hidden heredity is most pronounced for patients with apparently sporadic parasympathetic paragangliomas, with up to 34% of cases having a germline mutation in SDHD. 13 Clinical indications with high specifi city but low sensitivity for the detection of phaeochromocytomaparaganglioma syndrome (family history of phaeochromocytoma or paraganglioma, multifocal disease, younger age at onset, and malignant tumours) are insuffi cient for correct diagnosis of the syndrome. The detection of inherited phaeochromocytoma-paraganglioma syndrome is of major importance for patients with phaeochromocytoma and paraganglioma, as well as for their family members, since they are at an increased risk of developing multiple, various, and malignant neoplasms. 4, [14] [15] [16] Additionally, after identifi cation of an SDHB, SDHC, or SDHD germline mutation, surveillance can be off ered to the individual patient with the paraganglionic tumour and to any family members who carry the mutation. Mutation analysis of SDHB, SDHC, and SDHD has been advocated to diagnose phaeochromocytoma-para ganglioma syndrome in all cases of phaeochromocytoma and paraganglioma where there are no clear clinical or family indications for the syndrome. 16 Although SDH-mutation carriers will be identifi ed frequently by mutation analysis of all patients with phaeochromocytomas and paragangliomas, most cases will be without mutation, making this genetic-screening strategy a labour-intensive and fi nancially demanding procedure. Phaeochromocytomapara ganglioma syndrome tumours diff er from sporadic phaeochromocytomas and paragangliomas by the presence of SDHB, SDHC, or SDHD mutations, which are, except for a few incidental cases, 17, 18 not found in truly sporadic phaeochromocytomas and paragangliomas. Despite this genotypic diff erence, no reliable phenotypic discrimination between sporadic phaeochromocytomas and paragangliomas, and phaeochromocytomaparaganglioma syndrome-related tumours, is possible at present. In the present study we determined the value of SDHB immunohistochemistry for discriminating between SDH-related and non-SDH-related phaeochromocytomas and para gangliomas in large retrospective and prospective series in two diff erent centres. 
Methods

Patients
Procedures
Two diff erent primary antibodies against SDHB were used: mouse monoclonal clone 21A11 (NB600-1366; Novus Biologicals, Littleton, CO, USA; 1:50) and rabbit polyclonal HPA002868 (Sigma-Aldrich Corp; St Louis, MO, USA; 1:500). The antibodies were applied on routine FFPE archival tissues. 4-6 μm sections were cut and mounted on Starfrost Plus (Knittel Gläser; Braunschweig, Germany) glass slides. The sections were deparaffi nised, rehydrated, exposed to microwave heating in Tris-EDTA buff er, pH 9·0 or citrate buff er, pH 6·0 at 100°C for 15 min, rinsed in tap water followed by incubation in 3% H 2 O 2 in PBS for 20 min. The SDHB antibodies were diluted in normal antibody diluent (Klinipath, Duiven, Netherlands) and slides were incubated with 100 μL per slide overnight at 4°C, followed by rinsing in Tris-Tween 0·5%, pH 8·0. Dako ChemMate envision horseradish peroxidase was applied for 30 min (100 μL/slide; Dako envision kit, Glostrup, Denmark), followed by rinsing with phosphatebuff ered saline. Diaminobenzidine tetrahydrochloride (100 μL/slide; Dako envision kit) was applied for 5 min twice, after which the slides were rinsed with distilled water. Slides were counterstained with Harris haematoxylin for 1 min, rinsed with tap water, dehydrated, and covered with cover slips. In the negative control reactions, the primary antibodies were omitted from the dilution buff er, which in all instances resulted in a complete absence of staining. Human heart muscle, adrenal gland, liver, and colon tissues were used as positive controls. These tissues showed strong granular staining in the cytoplasm with both antibodies. In phaeochromocytoma and paraganglioma the normal stromal cells of the fi brovascular network surrounding the Zellballen of tumour cells served as an internal positive control for each sample, also showing strong granular cytoplasmatic staining as in the positive control samples. Pathologists who had no knowledge of the mutation status of the specimens scored the immunohistochemical results from the retrospective series from Rotterdam and Paris independently. The immunohistochemical results of the prospective series were scored by researchers or by pathologists, before mutation analyses were done.
Western blots were done with 50 5-μm sections (approximately 10 mg) cut from fi ve frozen phaeochromocytoma tissue samples from patients with germline mutations in SDHB (EX3del), SDHD (p.Asp92Tyr), RET (p.Cys634Arg), VHL (p.Arg64Pro), and NF1 (clinically determined). Additionally, the same amount of frozen tissue was taken from a lymph node of the patient carrying an SDHB mutation, and from a normal adrenal gland. These tissues were transferred into 100 μL 1×Laemmli sample buff er, followed by incubation for 15 min at room temperature. Next, the samples were stirred for 15 s, followed by incubation for 5 min at 100°C. Equal amounts of the samples were then run on a 10% SDS-PAGE gel. After electrophoresis the proteins were transferred to an Immobilon-P Membrane (Millipore, Temecula, CA, USA) and immunoblotted. Both 21A11 and HPA002868 antibodies were used for western blotting and an antibody against β-actin (Sigma-Aldrich; 1:10000) was used as a control for the amount of protein present on the blot.
To test whether absence of immunohistochemical staining for SDHB in the tumours correlated with decreased SDH enzyme activity, SDH enzyme histochemistry was done according to Pearse 19 HCO 3 , and 0·17 mmol/L Phenazine methosulfate (P9625, Sigma-Aldrich). After rinsing in water twice, the slides were incubated at 4°C for 15 min in formaline-macrodex solution (containing 10 mL 37% formaldehyde, 10 mL 1% CaCl 2 , 80 mL macrodex [Pharmalink, Stockholm, Sweden]). After rinsing the slides in water again three times, the slides were mounted with imsolmount (Klinipath, Duiven, Netherlands) and covered with cover slips. Snap frozen healthy triceps muscle tissue was used as a positive control. As negative 4, 20 For these analyses, DNA was retrieved from FFPE tumour and normal tissues or from peripheral blood, in the period from 1993 until 2008. DNA was isolated using described and standard procedures, and mutation analyses were done with or without pre-screening by single-strand conformation polymorphism analysis (SSCP) followed by direct, in-house, or commercial (Baseclear, Leiden, Netherlands) sequencing of PCR products. 13, 20, 21 Mutation analyses of the additional samples from other centres were done by sequencing on site and verifi ed at Erasmus MC and INSERM U970. Mutation analysis of all 34 sporadic cases was done by direct sequencing of the open reading frames, including the exon-intron boundaries, of the SDHB, SDHC, and SDHD genes. 4 The prospective series of 45 tumours was also investigated for SDHB, SDHC, and SDHD mutations by direct sequencing of the open reading frames including all exon-intron boundaries as described previously. 20 Additionally, this series was investigated for the presence of large genomic deletions in the SDH genes by multiplex ligation-dependent probe amplifi cation (MLPA) assay with a commercially available kit (SALSA MLPA P226; MRC Holland, Amsterdam, Netherlands).
Statistical analysis
Patients were grouped on the basis of the presence and absence of an SDH mutation, and sensitivity and specifi city of the SDHB immunohistochemistry to detect an SDH mutation were determined. Within the prospective series we tested for associations between SDHB immunohistochemistry test result and SDH mutation status using Fisher's exact test. 95% CI were calculated using the exact binomial method. Analyses were done with STATA, version 10.0.
Role of the funding source
None of the sponsors had any role in study design, data collection, analysis, interpretation of the data, or the writing of this article. FHN, JG, EK, JF, APGR, RRK, and WNMD had access to the raw data. The corresponding author had full access to all the data and the fi nal responsibility to submit the manuscript for publication.
Results
Immunohistochemical staining was done on all 220 tumour samples. Of these tumours, 102 had a germline SDH mutation (36 SDHB, fi ve SDHC and 61 SDHD) and all were negative for SDHB immunohistochemistry (fi gure 1A-C). In four SDH-mutated tumours (SDHB p.Cys98Arg and p.Pro197Arg, and SDHD p.Asp92Tyr and c.169_169+9delTGTATGTTCT) a weak and diff use cytoplasmic SDHB immunoreactivity was seen in the tumour cells, clearly distinct from the strong speckled pattern present in normal cells of the intratumoral fi brovascular network (fi gure 1C). However, independent tumour samples with the same mutation (SDHB p.Pro197Arg and SDHD p.Asp92Tyr) were clearly negative for SDHB immunostaining. Therefore, this weak diff use cytoplasmic staining in the tumour cells was considered to be a non-specifi c background artifact and scored as negative. 65 tumours had a germline mutation in RET (24 cases), VHL (29 cases), or NF1 (12 cases, diagnosed pheno typically), and all showed expression of SDHB by immunohistochemistry (fi gure 1D-F). In the remaining 53 tumours, of which six tumours were SDHB-negative, no germline mutation in the RET, VHL, SDHB, SDHC, or SDHD genes was seen, nor was any NF1 gene involvement detected. A summary of the results is listed in table 1 and comprehensive information on tumour characteristics, including type of mutation and results is presented in the webappendix.
In the prospective series, sensitivity and specifi city were 100% (95% CI 87-100) and 84% (60-97), respectively. Table 2 shows that there was a highly signifi cant association between the SDHB immunohistochemistry test result and the absence or presence of an SDH mutation (p<0·0001; Fisher's exact test). SDHB immunohistochemistry done on cryostat sections from three phaeochromocytomas, two with an SDHD mutation and one with a RET mutation, gave results comparable to FFPE tissue sections: speckled staining patterns in the normal cells and an absence of staining in SDHD-mutated tumour cells. This comparable SDHB immunoreactivity pattern on FFPE and frozen tissues is an additional indication for the specifi city of the immunohistochemistry results. The decreased expression of SDHB protein in both SDHB-mutated and SDHD-mutated tumours was confi rmed by western blotting (fi gure 2A). Additionally, the absence of SDH enzyme activity was determined by enzyme histochemistry. The SDHB-related and SDHD-related tumours showed no SDH activity, except for the normal cells of the intratumoral fi brovascular network, which showed strong staining (fi gure 2B). By contrast, strong SDH enzyme activity was present in the triceps muscle tissue and the RET-related tumour tissue (fi gure 2C).
Discussion
The results of this study show that SDHB immunohistochemistry on routine FFPE paragangliomas and phaeochromocytomas can reveal the presence of SDHB, SDHC, and SDHD germline mutations with a high degree of reliability. The absence of SDHB staining in tumour cells was found irrespective of whether SDHB, SDHC, or SDHD is mutated, and regardless of the type of mutation, whether missense, nonsense, splice site, or frameshift. The SDHB protein-expression results obtained by immunohistochemistry using both SDHB antibodies (Sigma mouse monoclonal 21A11 and Novus rabbit polyclonal HPA002868) were the same. Either antibody might be used for the immunohistochemical detection of SDHB.
Of the 220 independent tumours analysed, 102 had a germline SDH mutation (36 SDHB, fi ve SDHC, and 61 SDHD), and all were negative for SDHB immunostaining. 65 tumours had a germline mutation in RET (24 cases), VHL (29 cases) or NF1 (12 cases, diagnosed phenotypically), and all showed expression of SDHB by immunohistochemistry. In the remaining 53 tumours no germline mutation in the RET, VHL, SDHB, SDHC, or SDHD gene, nor NF1 gene involvement was detected, but six tumours were negative for SDHB immunostaining. The absence of SDHB protein in these six tumours might be caused by SDH mutations escaping detection by the DNA sequencing and MLPA methods used (eg, deleterious mutations in untranslated, intronic, or promoter regions of the genes, which were not investigated), or by epigenetic silencing of SDH genes. In two of these six patients without SDH mutations, but with SDHB immunohistochemistry-negative tumours, the clinical information was indicative of phaeo chromocytomaparaganglioma syndrome: one patient had a family history of paraganglioma and one patient suff ered from multiple paragangliomas (webappendix). Furthermore, three of the four other SDHB-negative tumours without SDH-gene mutations were diagnosed at a young age (webappendix; cases 179A, 180B, and 220C), indicating possible germline involvement. A negative SDH genetic testing in association with negative SDHB immunohistochemistry could indicate the possibility of a phaeochromocytoma or paraganglioma hereditary syndrome, and we recommend that the patient be followed up in the same way as for a proven phaeo chromocytoma or paraganglioma hereditary syndrome. There is a highly signifi cant association between the SDHB immunohistochemistry test result and the absence or presence of an SDH mutation. The SDHB immuno histochemical test has a high sensitivity and specifi city for the presence of an SDH mutation. The possibility that in the six SDHB-negative tumours without identifi ed SDH gene mutations the mutations escaped detection would mean that the sensitivity and specifi city of SDHB immunohistochemistry for the detection of phaeochromocytomaparaganglioma syn drome is even higher than estimated here. The reliability of the immunohistochemical results on FFPE tumour specimens is also indicated by the similar results obtained with two diff erent antibodies, applied on three diff erent tumour series in two diff erent laboratories (the retrospective series in Rotterdam and Paris, and prospective series in Rotterdam), and the concordant results obtained on cryostat sections, in western blotting, and by SDH-enzyme histochemistry. Our results show that in tumour cells with various mutations (SDHB; 15 diff erent missense, two diff erent nonsense, six diff erent frameshift, three diff erent exon deletions, three mutations probably aff ecting splicing), SDHC; two diff erent missense, one nonsense, and two exon deletions, and SDHD; fi ve diff erent missense, two diff erent nonsense, three diff erent frameshift, and three mutations probably aff ecting splicing, no immunoreactive SDHB protein could be detected. These results are in accordance with preliminary fi ndings by Douwes-Dekker and colleagues, 22 who reported generally decreased diff use cytoplasmic SDHB expression in 11 SDHD-related (two diff erent SDHD mutations) paragangliomas and strong granular expression in sporadic tumours and normal cells. Additionally, Dahia and colleagues 23 reported comparable decreased SDHB expression in fi ve SDHB-related, one SDHD-related, and six VHL-related phaeochromocytomas. However, in the present study we were able to discriminate VHL-related tumours from SDH-related phaeochromocytoma and paraganglioma on the basis of SDHB immuno histo chemistry, which could be the result of diff erences in the applied immunohistochemistry procedure or tissue processing.
The diff erences in SDHB protein concentrations are probably not the result of diff erences in transcriptional effi ciency, since there are indications that SDHB mRNA concentrations do not parallel SDHB protein abundance. 23 Additionally, it has been shown previously that, whatever SDH subunit is mutated, be it anchorage (SDHC and SDHD) or catalytic (SDHB), inactivation of an SDH gene induces a complete abolition of SDH enzyme activity in the tumour, suggesting a conformational change or a destabilisation and a subsequent proteolysis of the complex II. 7, 22, 24 Furthermore, Lima and colleagues 25 showed by crystallography the severe structural consequences on the SDHB protein of fi ve clinically validated SDHB missense mutations. Cervera and colleagues 26 recently obtained evidence that three missense-mutated SDHB proteins can reach the mitochondrion and localise normally, although two of three missense-mutated SDHB proteins showed decreased expression by western blotting compared with the wild-type protein. These results match with the recent evidence that most rare missense variants in genes are deleterious. 27 In the present study four tumours, positive for SDHB immunostaining, harboured non-synonymous polymorphisms (SDHB p.Ala3Gly, p.Arg11His, p.Ser163Pro, and SDHD p.His50Arg) without concomitant pathogenic SDH-gene mutation, indicating that these variants are indeed neutral polymorphisms. 15, 28 Biallelic inactivation of the SDHB, SDHC, or SDHD gene has been reported in SDH-related tumours. 17, 24, 29 Our results indicate that mutations in SDHB, SDHC, or SDHD lead to the same phenotypic consequence in the tumoursie, the absence of immunoreactive SDHB protein. Such observations have already been described for mutations in complex I genes, which were shown to aff ect the assembly and stability of both the whole complex I and other mitochondrial complexes, such as complex III. 30 The observed absence of SDHB immunoreactivity in all SDH-mutated tumours, shown by immunohistochemistry in both FFPE and frozen tumour tissues, and by western blotting after denaturing gel electrophoresis, with both a monoclonal antibody generated against cow SDHB and an affi nity-isolated polyclonal antiserum against a recombinant carboxyterminal part of human SDHB, provides strong evidence that no functional SDHB protein is present in SDH-mutated tumours. As previously reported in other mitochondrial disorders, it is therefore likely that altered assembly or complex stability is the fi rst consequence of SDH gene mutations, as opposed to catalytic site dysfunction. It confi rms the accuracy of immunological approaches for the diagnosis of mitochondrial diseases. 31 By use of our applied procedure, patients with phaeochromocytoma-paraganglioma syndrome with an apparently sporadic presentation can be detected by SDHB immunohistochemistry on paragangliomas and phaeochromocytomas. Additionally, it can be speculated that the syndromic involvement of tumours that have recently been described in relation with paragangliomas, such as gastrointestinal stromal tumours in the Carney-Stratakis dyad and familial renal-cell carcinomas, could also be detected by SDHB immunohistochemistry. 29, 32 In actual fact, tissue from one of these germline SDHB mutated renal-cell carcinomas was available for study, and this tumour seemed to be negative for SDHB expression (data not shown).
As for Lynch syndrome diagnostics, where the testing of tumours usually starts with immunohistochemistry for mismatch repair gene products, SDHB immunohistochemistry could have an important role in the future genetic testing of phaeochromocytomas and paragangliomas (fi gure 3). 33 Because of the simplicity of the standard immunohistochemical procedure and data interpretation, the immunohistochemistry test could easily be applied in diagnostic pathology services worldwide. It is technically and fi nancially feasible to routinely test all phaeochromocytoma and paraganglioma for SDHB expression, in particular in the absence of familial or clinical indications for a specifi c form of inherited phaeochromocytoma or paraganglioma. Our results show that SDHB, SDHC, and SDHD germline mutation testing is indicated only when tumours are immunohistochemically negative for SDHB expression. Obviously, our proposed diagnostic test can only be done after patients have been operated on and tumour tissue is available for study. The eff ect that our test will have on patient management is unclear, since international controversy exists regarding preoperative and postoperative genetic testing, and the eff ect on patient management. None theless, by routinely doing SDHB immuno histochemistry, hereditary syndromes caused by germline mutations in SDHB, SDHC, or SDHD could be identifi ed with a high degree of reliability.
